On 15 to 17 December 2021 a three-day trial took place to determine preliminary issues in a second action brought by Neurim against Mylan in relation to patents protecting the product Circadin (…
A person of ordinary skill in the art could not determine the effective dose of the active ingredient in Tecfidera from the original patent specification.
A West Virginia federal district court’s…
In recent years, the Court of Appeals for the Federal Circuit has invalidated or affirmed the invalidity of various biopharma patents under 35 U.S.C. § 112, which requires that a patent specification…
In the course of obtaining regulatory approval for a drug product in the United States, a pharmaceutical company will make numerous representations about its product in submissions to the Food and…
Photo Close-up shot of pills spilled from plastic can on white created by KostyaKlimenko
On 18 October 2021, the Russian IP Court rendered the decision in Geropharm vs. Novo Nordisk. While…
In Japanese patent litigation, calling expert witnesses is very rare and the parties usually try to prove common technical knowledge (CGK) by submitting documentary evidence, such as publications…
On 8 October 2021, His Honour Judge Hacon (sitting as a Judge of the High Court) handed down his decision in an action brought by Royalty Pharma Collection Trust (“Royalty Pharma”) for approximately …
In the pharma industry, constant battles have been taking place for many decades between innovators and generics. More recently, battles among innovators have also started to occur. This post…
In a surprising decision, the Federal Court has modified the law of patent term extensions in Australia, by clarifying that it's only the patentee's goods that are relevant to the proposed extension …
